Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- LSIP Signs 1st Agreements for Patents on Apoptosis, Stem Cells
January 24, 2011
- Pfizer Applies for Prevnar 13 in Adult Patients in US, Europe
January 24, 2011
- Takeda Licenses Biomarker for Alzheimer's Disease from Zinfandel
January 24, 2011
- Prospects for Simultaneous Global Development: 4
January 24, 2011
- Ono Enters Target Discovery Agreement with BioFocus for Autoimmune Disease
January 24, 2011
- Minodronate vs Raloxifene to Be Compared in IIT
January 24, 2011
- Astellas Expands Marketing Territory for Eligard
January 24, 2011
- Office of Medical Innovation to Begin Full Operation
January 24, 2011
- Daiichi Sankyo Transfers Marketing of Kremezin in Japan to MTPC
January 24, 2011
- BI, Eli Lilly Tie Up to Develop Antidiabetic Agents
January 24, 2011
- GSK Licenses Parkinson's Disease Drug from Impax
January 24, 2011
- AZ Enters 2nd Decade of Leap in 2011: President Kato
January 24, 2011
- Teijin Pharma to Market Kenketsu Venilon, Anact C in Kyushu
January 24, 2011
- Astellas to Review Strategic Alternatives for Prosidion
January 24, 2011
- Eisai Signs PPP to Increase Patients' Access to Medicines in India
January 24, 2011
- Kyowa Kirin to Reinforce GMP Compliance
January 24, 2011
- AnGes MG to Codevelop Antibacterial Spray with Hospital Group
January 24, 2011
- JMIRI Launches Web Service for Prescription Record Analysis
January 24, 2011
- Bayer, J&J Apply for Rivaroxaban for SPAF in the US, Europe
January 17, 2011
- MINCLEA for Inhibiting GI Peristalsis: ASKA, Nihon Pharm.
January 17, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…